Baseline genomic profile of cBTKi pretreated CLL patients. (A) Oncoprint of genomic alterations at baseline in patients with CLL who responded and those who did not respond to pirtobrutinib. (B) Oncoprint of BTK alterations detected at baseline, pirtobrutinib response, and outcome in patients harboring BTK mutations. CR, complete response; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; NE, not evaluable; PI3K, phosphoinositide 3-kinase; PR, partial response; PR-L, partial response with lymphocytosis; SD, stable disease; VUS, variant of unknown significance.